Page last updated: 2024-12-06

carbazeran

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Carbazeran is a synthetic derivative of the naturally occurring alkaloid, carbazole. It has been investigated for its potential anticancer properties and its ability to inhibit the growth of various types of cancer cells, including leukemia, breast cancer, and colon cancer. The mechanism of action of carbazeran is believed to involve the induction of apoptosis, or programmed cell death, in cancer cells. Carbazeran is currently in preclinical development and is being evaluated for its safety and efficacy in clinical trials.'

carbazeran: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID71983
CHEMBL ID77131
SCHEMBL ID122456
MeSH IDM0099456

Synonyms (43)

Synonym
CHEMBL77131
uk-31557
uk-31,557
70724-25-3
carbazeran (usan/inn)
D03386
carbazeran
1-(6,7-dimethoxyphthalazin-1-yl)piperidin-4-yl ethylcarbamate
[1-(6,7-dimethoxyphthalazin-1-yl)piperidin-4-yl] n-ethylcarbamate
FT-0664236
AKOS016010372
uk 31557
carbazeranum
carbazeran [usan:inn]
0n4i6k95p2 ,
1-(6,7-dimethoxy-1-phthalazinyl)-4-piperidyl ethylcarbamate
carbamic acid, ethyl-, 1-(6,7-dimethoxy-1-phthalazinyl)-4-piperidinyl ester
unii-0n4i6k95p2
carbazeranum [inn-latin]
carbazeran [inn]
carbazeran [usan]
SCHEMBL122456
DTXSID00220983
(4-{[4-(1-benzothiophen-2-yl)-2-pyrimidinyl]amino}phenyl)[4-(1-pyrrolidinyl)-1-piperidinyl]methanone
J-690342
EX-A884
SR-01000945000-1
sr-01000945000
mfcd00867107
carbazeran, >=96% (hplc)
NCGC00387169-01
BCP06512
2,4,5-tbutoxyethylester
AS-35118
uk31,557
uk 31,557
uk31557
Q27236989
A866557
AC-36820
1-(6,7-dimethoxyphthalazin-1-yl)piperidin-4-ylethylcarbamate
HY-B0051
CS-0006514

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
"The pharmacokinetic properties of drugs may be altered by kinetic deuterium isotope effects."( Deuterium isotope effects on drug pharmacokinetics. I. System-dependent effects of specific deuteration with aldehyde oxidase cleared drugs.
Clark, AJ; Gao, H; Obach, RS; Ripp, SL; Schildknegt, K; Sharma, R; Spracklin, DK; Strelevitz, TJ; Tremaine, LM; Vaz, AD, 2012
)
0.38

Bioavailability

ExcerptReferenceRelevance
"The bioavailability of carbazeran and the metabolism of carbon-14 labelled drug have been studied in the dog and man following oral administration."( A species difference in the presystemic metabolism of carbazeran in dog and man.
Elliott, HL; Hillis, WS; Kaye, B; Offerman, JL; Reid, JL, 1984
)
0.83
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (7)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency9.52210.01237.983543.2770AID1645841
GVesicular stomatitis virusPotency15.09160.01238.964839.8107AID1645842
cytochrome P450 2D6Homo sapiens (human)Potency16.93300.00108.379861.1304AID1645840
Interferon betaHomo sapiens (human)Potency15.09160.00339.158239.8107AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency15.09160.01238.964839.8107AID1645842
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency15.09160.01238.964839.8107AID1645842
cytochrome P450 2C9, partialHomo sapiens (human)Potency15.09160.01238.964839.8107AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (45)

Processvia Protein(s)Taxonomy
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (18)

Processvia Protein(s)Taxonomy
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (22)

Processvia Protein(s)Taxonomy
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (35)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1223518Drug metabolism in cryopreserved human hepatocytes assessed as aldehyde oxidase-mediated metabolite formation at 10 uM by LC-MS extracted ion chromatogram analysis in presence of hydralazine2012Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 40, Issue:2
Characterization of aldehyde oxidase enzyme activity in cryopreserved human hepatocytes.
AID220009Inhibition of cAMP Phosphodiesterase enzyme.1987Journal of medicinal chemistry, Feb, Volume: 30, Issue:2
In search of the digitalis replacement.
AID731932Ratio of fraction unbound in blood to fraction unbound in plasma in human2013ACS medicinal chemistry letters, Jan-10, Volume: 4, Issue:1
Discovery of the Highly Potent PI3K/mTOR Dual Inhibitor PF-04979064 through Structure-Based Drug Design.
AID1219925Drug metabolism in guinea pig liver S9 fraction assessed as carbazeran glucuronide formation in presence of NADPH and UDP-glucuronic acid and alamethicin by UV chromatogram method2012Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3
Deuterium isotope effects on drug pharmacokinetics. I. System-dependent effects of specific deuteration with aldehyde oxidase cleared drugs.
AID731933Fraction unbound in human plasma2013ACS medicinal chemistry letters, Jan-10, Volume: 4, Issue:1
Discovery of the Highly Potent PI3K/mTOR Dual Inhibitor PF-04979064 through Structure-Based Drug Design.
AID1219917Half life in Sprague-Dawley rat at 5 mg/kg, po2012Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3
Deuterium isotope effects on drug pharmacokinetics. I. System-dependent effects of specific deuteration with aldehyde oxidase cleared drugs.
AID40531Positive inotropic effects by direct or indirect beta-1 adrenergic receptor activation.1987Journal of medicinal chemistry, Feb, Volume: 30, Issue:2
In search of the digitalis replacement.
AID1219924Drug metabolism in human hepatocytes assessed as carbazeran glucuronide formation by UV chromatogram method2012Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3
Deuterium isotope effects on drug pharmacokinetics. I. System-dependent effects of specific deuteration with aldehyde oxidase cleared drugs.
AID1223504Oral bioavailability in human2012Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 40, Issue:2
Characterization of aldehyde oxidase enzyme activity in cryopreserved human hepatocytes.
AID731931Plasma clearance in iv dosed human2013ACS medicinal chemistry letters, Jan-10, Volume: 4, Issue:1
Discovery of the Highly Potent PI3K/mTOR Dual Inhibitor PF-04979064 through Structure-Based Drug Design.
AID1219907Half life in Sprague-Dawley rat at 5 mg/kg, iv2012Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3
Deuterium isotope effects on drug pharmacokinetics. I. System-dependent effects of specific deuteration with aldehyde oxidase cleared drugs.
AID1219926Drug metabolism in rat hepatocytes assessed as carbazeran glucuronide formation by UV chromatogram method2012Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3
Deuterium isotope effects on drug pharmacokinetics. I. System-dependent effects of specific deuteration with aldehyde oxidase cleared drugs.
AID1219916Cmax in Sprague-Dawley rat at 5 mg/kg, po2012Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3
Deuterium isotope effects on drug pharmacokinetics. I. System-dependent effects of specific deuteration with aldehyde oxidase cleared drugs.
AID1219913Cmax in Hartley guinea pig at 5 mg/kg, po2012Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3
Deuterium isotope effects on drug pharmacokinetics. I. System-dependent effects of specific deuteration with aldehyde oxidase cleared drugs.
AID1215672Drug metabolism in pooled human hepatocytes assessed as aldehyde oxidase-mediated drug metabolism at 10 uM up to 120 mins by HPLC analysis in presence of 50 uM of hydralazine2012Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 40, Issue:7
Hydralazine as a selective probe inactivator of aldehyde oxidase in human hepatocytes: estimation of the contribution of aldehyde oxidase to metabolic clearance.
AID1223503Total clearance in human2012Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 40, Issue:2
Characterization of aldehyde oxidase enzyme activity in cryopreserved human hepatocytes.
AID1215671Drug metabolism in pooled human hepatocytes assessed as aldehyde oxidase-mediated drug metabolism at 10 uM up to 120 mins by HPLC analysis in presence of 25 uM of hydralazine2012Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 40, Issue:7
Hydralazine as a selective probe inactivator of aldehyde oxidase in human hepatocytes: estimation of the contribution of aldehyde oxidase to metabolic clearance.
AID1525700Substrate activity at aldehyde oxidase in guinea pig liver cytosol assessed as enzyme-mediated drug uptake at 1 uM2019Journal of medicinal chemistry, 12-26, Volume: 62, Issue:24
Metabolism by Aldehyde Oxidase: Drug Design and Complementary Approaches to Challenges in Drug Discovery.
AID1219915AUC in Sprague-Dawley rat at 5 mg/kg, po2012Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3
Deuterium isotope effects on drug pharmacokinetics. I. System-dependent effects of specific deuteration with aldehyde oxidase cleared drugs.
AID1525699Substrate activity at aldehyde oxidase in rat liver cytosol assessed as enzyme-mediated drug uptake at 1 uM2019Journal of medicinal chemistry, 12-26, Volume: 62, Issue:24
Metabolism by Aldehyde Oxidase: Drug Design and Complementary Approaches to Challenges in Drug Discovery.
AID1525701Substrate activity at aldehyde oxidase in human hepatocytes assessed as enzyme-mediated drug uptake at 1 uM2019Journal of medicinal chemistry, 12-26, Volume: 62, Issue:24
Metabolism by Aldehyde Oxidase: Drug Design and Complementary Approaches to Challenges in Drug Discovery.
AID1219905Half life in Hartley guinea pig at 5 mg/kg, iv2012Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3
Deuterium isotope effects on drug pharmacokinetics. I. System-dependent effects of specific deuteration with aldehyde oxidase cleared drugs.
AID1219912AUC in Hartley guinea pig at 5 mg/kg, po2012Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3
Deuterium isotope effects on drug pharmacokinetics. I. System-dependent effects of specific deuteration with aldehyde oxidase cleared drugs.
AID1219914Half life in Hartley guinea pig at 5 mg/kg, po2012Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3
Deuterium isotope effects on drug pharmacokinetics. I. System-dependent effects of specific deuteration with aldehyde oxidase cleared drugs.
AID1223502Clearance in cryopreserved human hepatocytes at 1 uM up to 120 mins by LC/MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 40, Issue:2
Characterization of aldehyde oxidase enzyme activity in cryopreserved human hepatocytes.
AID1223505Drug metabolism in cryopreserved human hepatocytes assessed as aldehyde oxidase-mediated parent compound retention time at 10 uM by LC-MS extracted ion chromatogram analysis2012Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 40, Issue:2
Characterization of aldehyde oxidase enzyme activity in cryopreserved human hepatocytes.
AID731935Half life in human liver S9 fraction in presence of NADPH2013ACS medicinal chemistry letters, Jan-10, Volume: 4, Issue:1
Discovery of the Highly Potent PI3K/mTOR Dual Inhibitor PF-04979064 through Structure-Based Drug Design.
AID1525698Substrate activity at aldehyde oxidase in human liver cytosol assessed as enzyme-mediated drug uptake at 1 uM2019Journal of medicinal chemistry, 12-26, Volume: 62, Issue:24
Metabolism by Aldehyde Oxidase: Drug Design and Complementary Approaches to Challenges in Drug Discovery.
AID1219906AUC in Sprague-Dawley rat at 5 mg/kg, iv2012Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3
Deuterium isotope effects on drug pharmacokinetics. I. System-dependent effects of specific deuteration with aldehyde oxidase cleared drugs.
AID1219904AUC in Hartley guinea pig at 5 mg/kg, iv2012Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3
Deuterium isotope effects on drug pharmacokinetics. I. System-dependent effects of specific deuteration with aldehyde oxidase cleared drugs.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (21)

TimeframeStudies, This Drug (%)All Drugs %
pre-19908 (38.10)18.7374
1990's1 (4.76)18.2507
2000's0 (0.00)29.6817
2010's8 (38.10)24.3611
2020's4 (19.05)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 22.68

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index22.68 (24.57)
Research Supply Index3.14 (2.92)
Research Growth Index4.17 (4.65)
Search Engine Demand Index23.28 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (22.68)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (4.76%)5.53%
Reviews5 (23.81%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other15 (71.43%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]